Summary
Here's Why Sagimet Biosciences Inc. (SGMT) Could be Great Choice for a Bottom Fisher
After losing some value lately, a hammer chart pattern has been formed for Sagimet Biosciences Inc. (SGMT), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Wall Street Analysts Believe Sagimet Biosciences Inc. (SGMT) Could Rally 298.5%: Here's is How to Trade
The mean of analysts' price targets for Sagimet Biosciences Inc. (SGMT) points to a 298.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Sagimet Biosciences: Making The Bull Case For Differentiated Denifanstat
Sagimet Biosciences receives a Buy rating, driven by denifanstat's potential in MASH and acne, despite higher risk. Denifanstat met all endpoints in Phase 2b MASH and Phase 3 China acne trials, supporting optimism for US acne Phase 3. SGMT's near-term catalysts include US Phase 3 acne trial initiation and milestone payments from China partner Ascletis.
Sagimet Biosciences Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 John H. Burbank III Passport Capital LLC | 952,996 | $6.22M | $7.14M | $923,457.51 | 14.85% |
 Point72 Asset Management LP Point72 Asset Management LP | 187,564 | $1.1M | $1.34M | $240,734.08 | 21.84% |
 Richard Slavik Newbridge Financial Services Group Inc. | 1,500 | $6,750 | $11,212.5 | $4,462.5 | 66.11% |
 Rekah Franca Catalyst Funds Management Pty Ltd. | 13,900 | $72,628 | $103,902.5 | $31,274.5 | 43.06% |
 Li Peng China Universal Asset Management Co. Ltd. | 5,501 | $32,256.11 | $38,892.07 | $6,635.96 | 20.57% |
Sagimet Biosciences Inc. (SGMT) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Sagimet Biosciences Inc. ever had a stock split?
Sagimet Biosciences Inc. Profile
| Biotechnology Industry | Healthcare Sector | David Happel CEO | NASDAQ (NMS) Exchange | 786700104 CUSIP |
| US Country | 16 Employees | - Last Dividend | - Last Split | 14 Jul 2023 IPO Date |
Overview
Sagimet Biosciences Inc., originally founded as 3-V Biosciences, Inc., underwent a rebranding in August 2019 to better reflect its focused mission in the biomedical field. This clinical-stage biopharmaceutical company is at the forefront of developing innovative treatments targeting diseases caused by dysfunctional lipid metabolism pathways. With its incorporation in 2006, Sagimet Biosciences has dedicated its efforts to exploring the potential of fatty acid synthase (FASN) inhibitors. These compounds have shown promise in addressing a variety of conditions linked to lipid metabolism, underlying the company's commitment to advancing healthcare solutions from its headquarters in San Mateo, California. Its research and development pivot around Denifanstat and TVB-3567, reflecting a broader strategy to combat prevalent health issues like nonalcoholic steatohepatitis (NASH) and specific cancer types, along with other conditions such as acne that denote significant unmet medical needs.
Products and Services
-
Denifanstat (Lead Drug Candidate)
As the flagship product of Sagimet Biosciences, Denifanstat signifies a breakthrough in the treatment of nonalcoholic steatohepatitis (NASH), a serious liver condition lacking effective FDA-approved treatments. This innovative therapy, derived from the company’s proprietary research into fatty acid synthase (FASN) inhibitors, showcases Sagimet’s commitment to addressing diseases with significant unmet needs. In addition to NASH, Denifanstat has the potential to offer a novel treatment solution for acne, further demonstrating the broad therapeutic applications of FASN inhibitors in managing conditions linked to lipid metabolism dysfunctions.
-
TVB-3567 (FASN Inhibitor for Cancer)
TVB-3567 stands as Sagimet Biosciences’ pivotal entry into cancer therapy, embodying the company's innovative approach towards leveraging FASN inhibitors against various cancer types. This development aligns with the growing recognition of metabolic pathways, such as those governed by fatty acid synthase, as critical points of intervention in cancer treatment. Sagimet’s pursuit of TVB-3567 underscores a strategic focus on expanding the utility of its FASN inhibitor platform to tackle the complexities of cancer, aiming to provide patients with new, effective therapeutic options.
